

Funding sources

LUNG CANCER EUROPE (LUCE)

2024

LUCE Industry related income						
Name of company/funder	Amount of income	Currency	% of overall organisation's income			
AMGEN	52'756.00	CHF	7.47%			
GILEAD SCIENCES IRELAND	28'776.00	CHF	4.07%			
LIFE TECHNOLOGIES	28'557.00	CHF	4.04%			
HOFFMANN LA ROCHE	57'114.00	CHF	8.08%			
BRISTOL-MYERS	63'063.00	CHF	8.93%			
PFIZER	59'094.00	CHF	8.36%			
AstraZeneca Pharmaceuticals	59'448.00	CHF	8.41%			
TAKEDA	29'724.00	CHF	4.21%			
NOVARTIS	24'770.00	CHF	3.51%			
BAYER	24'770.00	CHF	3.51%			
MERK HEALTHCARE	24'770.00	CHF	3.51%			
PIERRE FABRE MEDIKAMENT	9'908.00	CHF	1.40%			
PHARMA MAR SPAIN	9'908.00	CHF	1.40%			
BOEHRINGER INGELHEIM	34'678.00	CHF	4.91%			
REGENERON PHARMACEUTICALS	44'311.00	CHF	6.27%			
ELI LIILLY BENELUX	17'616.60	CHF	2.49%			
BLUEPRINT	8'333.40	CHF	1.18%			
JANSSEN	43'137.00	CHF	6.11%			
MSD INTERNATIONAL	28'410.00	CHF	4.02%			
PATIENT ADVISORY	28'872.94	CHF	4.09%			
Subtotal	678'016.94	CHF	95.97%			

LUCE Non-Industry related income - public funding						
Name of company/funder	Amount of income	Currency	% of overall organisation's income			
OTHER REFUNDS NON-INDUSTRY	2'112.38	CHF	0.30%			
Subtotal	2'112.38	CHF	0.30%			

LUCE Non-Industry related income						
Name of company/funder	Amount of income	Currency	% of overall organisation's income			
MEMBER CONTRIBUTION	5'023.35	CHF	0.71%			
SPACETIME	15'000.00	CHF	2.12%			
OTHER REFUNDS NON-INDUSTRY	6'344.45	CHF	0.90%			
Subtotal	26'367.80	CHF	3.73%			

TOTAL	706'497.12	CHF 100.00%	

Information required to be included on organisation's website

Funding sources @ URL LUCE

Overal proportion of industry and non-industry Industry: 95.97%; Non-Industry: 4.03%

Percentage of the highest contribution from a single company 8.93% of overall organizations income